SCHEMBL7668016

SCHEMBL7668016

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(NC(=O)c2cccc(Cl)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 2/20 0.58
MAPT P10636 3/20 0.58
TP53 P04637 1/20 0.58
GAA P10253 2/20 0.53
KDM4E B2RXH2 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
POLB P06746 1/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
STAT3 P40763 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 3/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PTBP1 P26599 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7671404 0.88 GPR17 (0.59) GPR17MAPTTP53GAAMEN1
SCHEMBL7670320 0.88 MEN1 (0.58) GPR17MAPTMEN1KMT2ASTAT3
SCHEMBL7671859 0.87 PRMT1 (0.56) MAPTTP53GAAPOLBMEN1
SCHEMBL7582747 0.87 LMNA (0.65) POLBMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7672669 0.87 LMNA (0.62) GPR17MAPTTP53GAAKDM4E
SCHEMBL7668179 0.85 KMT2A (0.59) GPR17MAPTGAAPOLBMEN1
SCHEMBL7670533 0.83 MAPT (0.66) GPR17MAPTTP53GAAKDM4E
SCHEMBL7663141 0.83 GPR27 (0.59) MAPTKDM4EMEN1KMT2ASTAT3
SCHEMBL7663740 0.82 ALDH1A1 (0.65) MEN1KMT2ALMNASMN1; SMN2
SCHEMBL7671694 0.82 KMT2A (0.55) MAPTKDM4ETDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed